CN102210815A - Chinese medicine composition with functions of improving myocardial ischemia and blood viscosity and preparation method thereof - Google Patents
Chinese medicine composition with functions of improving myocardial ischemia and blood viscosity and preparation method thereof Download PDFInfo
- Publication number
- CN102210815A CN102210815A CN 201010142461 CN201010142461A CN102210815A CN 102210815 A CN102210815 A CN 102210815A CN 201010142461 CN201010142461 CN 201010142461 CN 201010142461 A CN201010142461 A CN 201010142461A CN 102210815 A CN102210815 A CN 102210815A
- Authority
- CN
- China
- Prior art keywords
- chinese medicine
- blood
- medicine composition
- myocardial ischemia
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a Chinese medicine composition with functions of improving myocardial ischemia and blood viscosity, which is a medicament prepared from the following medicinal raw materials in parts by weight: 4-8 parts of panax notoginseng saponins, 4-8 parts of gynostemma pentaphylla saponins, 3-5 parts of bamboo leaf extract and 15-30 parts of leech fine-powder. Proved by pharmacodynamic experiments, the Chinese medicine composition disclosed by the invention has the functions of improving hemorheology, breakage of the myocardial ischemia, reducing myocardial oxygen consumption and protecting cardiac muscle cells. The invention further discloses a preparation method of the Chinese medicine composition with functions of improving myocardial ischemia and blood viscosity.
Description
Technical field
The present invention relates to a kind of Chinese medicine composition that improves myocardial ischemia and the effect of blood viscous state that has; In addition, the invention still further relates to the preparation method of this Chinese medicine composition.
Background technology
Although the most countries of cardiovascular death rate except that East Bloc all has decline in various degree over nearly 30 years, but it is still majority state primary cause of death of male more than 45 years old, in the women then is second cause of the death that is only second to tumor, is having a strong impact on human life expectancy and life quality.
Myocardial ischemia is meant that the hemoperfusion of heart reduces, and causes the oxygen supply of heart to reduce, and energy metabolism of myocardial is undesired, can not support a kind of pathological state of heart operate as normal.High blood viscosity (or claiming blood high viscosity syndrome) is because one or more blood viscous factors raise, and blood transition thickness, slow blood flow are caused, and is the clinical pathology syndrome of characteristics unusually with blood rheology parameter.Generally, it has been exactly the excessive thickness of blood, be owing to erythrocyte aggregation bunchiness in the blood, lose due gap and distance, perhaps the crooked deformability of erythrocyte by small blood capillary the time descends in the blood, the viscosity of blood is increased, and circulation resistance increases, due to microcirculation blood flow is not smooth.
In the pathology development, the two is that cause effect relation is arranged usually.The blood viscosity height, the hemocyte deformability is poor, and tube wall causes the oxygen supply of heart to reduce because hyperlipemia causes the lipid plaque deposition, and sclerosis of blood vessels can have a strong impact on supply of blood flow in addition, and energy metabolism of myocardial is undesired, causes myocardial ischemia-anoxemia even infarction.
Therapeutic scheme act as the expansion heart coronary artery for selecting nitric acid lipid drug (as the different Pyrusussuriensis fat of single nitric acid or its slow release formulation), increases blood supply of cardiac muscle, reduces myocardial oxygen consumption; But have headache, feel sick, vomiting, even can cause side effect such as blood pressure drops, reflex tachycardia when heavy dose of.
The traditional Chinese medical science thinks that qi depression to blood stasis is the important pathogenesis of cardiovascular disease, treatment is many based on blood circulation promoting and blood stasis dispelling, because safe, effective, stable, the few side effects of Chinese medicine, controlled characteristic, so use Chinese medicine getting more and more at present in cardiovascular disease, we have retrieved disclosed, the relevant patent documentation of Chinese medicine composition with improving myocardial ischemia and blood viscous state finds no same or analogous pharmaceutical composition, and its pertinent literature has:
Disclose a kind of compound red sage root preparation as Chinese patent CN1421239A on 06 04th, 2003, said preparation is made by following raw material: Radix Salviae Miltiorrhizae extract 4-60 weight portion, Radix Notoginseng extract 2-18 weight portion, Borneolum Syntheticum 1-10 weight portion.Its drug effect has and resists myocardial ischemia and effects such as anti-platelet aggregation, treatment coronary heart disease, angina pectoris, myocardial infarction, cerebral thrombosis.
It is the pharmaceutical composition of active component with ligustrazine and danshensu that Chinese patent CN101596196A disclosed a kind of on the 09th in December in 2009, the purity of ligustrazine and danshensu is more than or equal to 98%, this pharmaceutical composition can be used for treating coronary heart disease, angina pectoris, ischemic cerebral thrombosis, atherosclerosis, myocardial ischemia or myocardial infarction, chronic viral hepatitis B hepatic fibrosis, fatty liver, senile dementia and cancer etc.
Chinese patent CN101336936A discloses a kind of compound thrombolytic TONGXINLUO JIAONANG and preparation method thereof on 01 07th, 2009, the invention provides a kind of compound thrombolytic TONGXINLUO JIAONANG and preparation method thereof, be to form by Hirudo, two kinds of medicine synergistic combination of aspirin, according to component weight proportion Hirudo powder: aspirin=18: 1, scale goes out the weight separately of two flavor medicines, after mixing, stirring, in incapsulating with every 475mg consumption, packed again or box-packed.Be applicable to the prevention of cerebrovascular sclerosis, blood viscosity raises, cerebral thrombosis, the chest severe pain that angina pectoris, myocardial infarction cause etc.
Summary of the invention
Traditional decocting medicine is very inconvenient, and the water yield and the duration and degree of heating are difficult to control, and carry difficulty, and play a role by multicomponent, many target spots.Compound Chinese medicinal preparation will making a breakthrough property progress, the drug matching prescription will be risen to the component level from the decoction pieces level, it is clear to develop ingredient, action target spot is clear and definite, effect link and mechanism are clear, the new medicine prescription that dose-effect relationship is optimized between medicine.
Technical problem to be solved by this invention is that propose a kind of has the Chinese medicine composition that improves myocardial ischemia and the effect of blood viscous state.Chinese medicine composition of the present invention belongs to the component compatibility preparation of secondary development, it utilizes component clear, action target spot is clear and definite, mechanism of action and link clearly active component are used as medicine, form best compatibility with crude drug fine powder that should not high temperature process, improve myocardial ischemia and blood viscous state effect is remarkable, not only strengthen pharmaceutical purity and therapeutic effect, also overcome the inconvenience of traditional decocting medicine simultaneously, standing time can not be long etc. shortcoming.
In order to solve the problems of the technologies described above, the present invention proposes, and to have the Chinese medicine composition that improves myocardial ischemia and the effect of blood viscous state be the medicament that is prepared from by following raw materials by weight proportions: Radix Notoginseng total arasaponins 4--8 part; Herb Gynostemmae Pentaphylli total glycosides 4--8 part; Folium Bambosae extract 3--5 part; Hirudo fine powder 15--30 part.
Preferably, the above-mentioned weight proportion with crude drug in the Chinese medicine composition that improves myocardial ischemia and the effect of blood viscous state of the present invention is as follows: 5 parts of Radix Notoginseng total arasaponinss; 5 parts of Herb Gynostemmae Pentaphylli total glycosides; 4 parts of Folium Bambosae extract; 20 parts of Hirudo fine powders.
Radix Notoginseng is the root of panax araliaceae plant Panax notoginseng (Burk.) F.H.Chen, and sweet and slightly bitter taste is warm in nature, returns liver, stomach warp.Function cures mainly and is dissipating blood stasis hemostasis, subduing swelling and relieving pain.Have good hemostasia effect, significant hemopoietic function; And can tighten and improve the arteria coronaria microcirculation.Compendium of Material Medica cloud: " Radix Notoginseng hemostasis, the blood that looses, analgesic therapy." " jade is seized medicine and separated " cloud: " Radix Notoginseng and battalion hemostasis, the clots absorbing of promoting blood circulation, clots absorbing blood and hold back fresh blood." its main active effective ingredient Radix Notoginseng total arasaponins is widely used in clinical; as clinical XUESAITONG ZHUSHEYE commonly used is exactly the Radix Notoginseng total arasaponins preparation; studies show that Radix Notoginseng total arasaponins can make that the sweet acid of ring gland (CAMP) content increases in the platelet; reduce the generation of thromboxane A2; anticoagulant; thus reduce plasma viscosity (medicine and clinical, 2006,14 (1): 66-67).Can also significantly alleviate rat heart muscle ischemia pathology damage degree (Chinese medicine and clinical, 2003 due to the isoproterenol; 3 (3): 229-233).
Herb Gynostemmae Pentaphylli is the herb of cucurbitaceous plant Herb Gynostemmae Pentaphylli Gynostemma pentaphyllum (Thunb.) Mak..Cold; Bitter; Return lung, spleen, kidney channel.Aspect cardiovascular, blood pressure lowering is arranged, blood fat reducing, blood sugar lowering, suppresses thrombotic effect at arteriosclerosis.Main chemical compositions has Saponin, sterols, flavonoid.Compendium of Material Medica, " national Chinese herbal medicine compilation " record: drink Herb Gynostemmae Pentaphylli, treat tracheitis, pharyngolaryngitis, migraine, blood pressure lowering, blood fat reducing, help sleep etc.Studies show that it has the reduction whole blood viscosity, plasma viscosity, the effect of erythrocyte aggregation index (Third Military Medical University's journal, 2007; 29 (15): 1497-1499).
Folium Bambusae is the leaf of grass phyllostachys nigra (lodd.ex lindl.) munro var.henonis (miff.) spapf et rendle (bamboo).Sweet, light, tremble with fear, go into the heart, lung, gallbladder, stomach warp.The Folium Bambosae extract effective ingredient comprises flavone, phenolic ketone, anthraquinone, lactone, polysaccharide, aminoacid, trace element etc., has the effect of good free radical resisting, antioxidation, defying age, resisting fatigue, blood fat reducing, prevention cardiovascular and cerebrovascular disease.Discover that Folium Bambusae total flavones is by suppressing the caspase-3 activated pathway of cytochrome C mediation, irritate the cardiac cellular apoptosis that causes again thereby suppressed ischemia, reach the effect (combination of Chinese and Western medicine cardiovascular and cerebrovascular disease magazine that alleviates or prevent myocardial ischemia reperfusion injury; 2007; 5 (2): 125-126).
Hirudo, the popular name Hirudo, growth and breeding in landlocked freshwater is the traditional extraordinary medicinal aquatic animal of China, salty in the mouth, hardship, property is flat, and is slightly poisonous.Have effects such as treatment apoplexy, hypertension, the clear stasis of blood, amenorrhea, traumatic injury.The clinical blood stasis that is usually used in is main various diseases, Compendium of Material Medica record " salty flavor acting on blood, the bitter blood that wins.The salty hardship of Hirudo to remove poultry blood, is a Liver Channel blood system medicine, so can lead to the poly-blood of Liver Channel ".Later age, Zhang Xichun praised this medicine: " deposit blood stasis and do not hinder fresh blood, the elite of pure lines water generates, and is at all harmless in edema caused by disorder of QI, and blood stasis is silently in invisible, and true good medicine also ".Studies show that Hirudo has inhibitory action to platelet activation, help alleviating thrombosis and vasospasm (the medical world, 2009 of bringing out behind the plaque rupture; 11 (4): 25-26).Hirudo preparation such as supermicro Tongxinluo Chinese medicine composition (Chinese patent CN1954825A, open day on 05 02nd, 2007) have the syndrome of blood stasis of inhibition rat platelet aggregation, improve its fibrinolytic, reduce the effect of its plasma viscosity.
The crude drug Radix Notoginseng total arasaponins is prepared from by the following step in the Chinese medicine composition of the present invention: notoginseng decoction piece (Araliaceae Radix Notoginseng Panax pseudo-ginseng var.notoginseng) is pulverized, ethanol with 75% extracts each chemical constituent in the Radix Notoginseng reed head earlier, filter, merging filtrate, be evaporated to certain volume, centrifugal, promptly get upper prop solution, use separation such as macroporous resin to go out compositions such as polysaccharide, flavone.Again by n-butanol extraction, activated carbon decolorizing, the purified water washing, method purification such as acetone precipitation, last drying is pulverized, sieve, mixings get finished product.Quality inspection: adopt ultraviolet spectrophotometry to detect content of the total saponins in radix notoginseng 〉=95%.
The crude drug Herb Gynostemmae Pentaphylli total glycosides is prepared from by the following step in the Chinese medicine composition of the present invention: (bitterness Herb Gynostemmae Pentaphylli gynostemma pentaphyllum (thunb) mak) is crushed to 10～20 order coarse powder with gynostemma pentaphyllum herb, reuse 85% alcohol reflux 3 times, each 2 hours, medicinal residues discard, get supernatant, crossing liquid measure is 8: 6: 6 times of amounts..It heavily is 1.15 that extracting solution is evaporated to ratio of specific heat.With the thick extractum after the compression, add deionized water sedimentation 3 times, each water consumption is 5: 4: 3.Get the supernatant upper prop: the DM130 resin absorption, 80% ethanol elution, the inspection of TLC thin layer is known.It heavily is 1.15 that the eluent vacuum decompression is concentrated into ratio of specific heat, and spray drying is pulverized, sieving forms.Quality inspection: adopt ultraviolet spectrophotometry to detect total saponin content of gynostemma pentaphyllum 〉=98%.
Raw material medical bamboo leaf extract is prepared from by the following step in the Chinese medicine composition of the present invention: raw material is chosen the Folium Bambusae (Herba Lophatheri Lophatherum gracile Bongn) of acceptance(check), go in the multi-function extractor, add 10 times of pure tap waters of amount, 1.5h is extracted in hot reflux.Extraction finishes, and feed liquid is gone into vacuum concentration pot and concentrated (require vacuum at 0.06-0.08mpa, thickening temperature is at 60-80 ℃) through behind the filter, after feed liquid is concentrated into 1/8 volume, crosses 80 eye mesh screens and emits feed liquid, non-shock chilling.After go into the tube centrifuge centrifugalize, the about per minute of centrifugal rotational speed 14000 changes.Get supernatant, go in the extractor, carry out liquid-liquid extraction with the n-butyl alcohol of 10 times of volumes, after 4h was stirred in insulation (35-40 ℃), supernatant was got in cooling, static.At 40 ℃ of left and right sides concentrating under reduced pressure, when concentrating the 100L volume, add pure water 40L, eject organic solvent, be concentrated into material liquid volume and reach about 25L, cross 80 eye mesh screens.Spray drying, 185～190 ℃ of inlet temperature, 85～90 ℃ of leaving air temps.Dry powder is collected to sieve and is formed.Quality inspection: adopt ultraviolet spectrophotometry to detect Folium Bambusae total flavones content 〉=24%.
Raw material liquid medicine trematodiasis fine powder in the Chinese medicine composition of the present invention (eurysome golden thread leech Whitmania pigra Whitman) is prepared from by the following step: with the cold drying of raw material Hirudo, baking temperature must not be above 50 ℃, after coarse pulverization, again at-20 ℃ of low temperature, the above fine powder of freezing ultra-fine one-tenth 400 orders, standby.
The present invention is above-mentioned, and to have the preparation method of the Chinese medicine composition that improves myocardial ischemia and the effect of blood viscous state as follows: take by weighing Radix Notoginseng total arasaponins, Herb Gynostemmae Pentaphylli total glycosides, Folium Bambosae extract and Hirudo pulvis subtilis respectively according to weight proportion, and with above-mentioned four kinds of crude drug uniform mixing; Evenly spray said mixture with 95% ethanol, wet granulation, cross 20-30 order granule screen cloth, wet granular is put into drip pan carry out freeze-day with constant temperature, baking temperature must not be above 50 ℃, dry 6-7 hour to moisture be 8%, the granule that drying is good is put into granulation machine and is carried out granulate, make the above capsule, tablet or granule of pharmaceutics according to conventional method: capsule is filled net content 430mg/ grain; Tablet is for adding suitable adjuvant, tabletting, coating promptly, every net content 400mg; Granule is every bag of net content 400mg.
Embodiment subsequently will prove, Chinese medicine composition of the present invention can reduce low viscosity, packed cell volume, the erythrocyte aggregation index cut of whole blood that epinephrine immersion method on the rocks duplicates the Blood stasis rat model, can significantly reduce erythrocytic aggregation extent, obviously improve blood viscosity; In addition, Chinese medicine composition of the present invention can reduce isoproterenol and prepare myocardial infarction and ischemia model rat blood serum LDH, CK, MDA activity, increases the SOD activity, reduces the T wave-amplitude, and histopathologic slide shows that myocardial damage obviously alleviates, and the effect that improves myocardial ischemia is promptly arranged.
The specific embodiment
Below in conjunction with specific embodiment, further set forth the present invention.These embodiment are interpreted as only being used to the present invention is described and are not used in restriction protection scope of the present invention.After the content of having read the present invention's record, those skilled in the art can make various changes or modifications the present invention, and these equivalences change and modify and fall into claim of the present invention institute restricted portion equally.
According to the disclosed technical scheme of summary of the invention, make the capsule preparations (hereinafter referred to as the BC capsule, capsule is filled net content 430mg/ grain) of Chinese medicine composition of the present invention, and carry out following effect experiment with this capsule preparations.
Effect experiment 1:BC capsule is to the hemorheological influence of stasis syndrome disease rat model
The SD rat, SD rat, 70, male, body weight (200 ± 20) g is divided into 7 groups at random, be respectively normal group, model group, aspirin group (100mg/kg), TONGXINLUO JIAONANG group (500mg/kg), BC capsule low dose group (242mg/kg), dosage group (484mg/kg) in the BC capsule, BC capsule in high dose group (968mg/kg), every group each 10.Medicine is dissolved in the deionized water of 2ml equal gastric infusion, every morning 1 time.Normal and model control group gives the Isodose deionized water and irritates stomach.Successive administration 7 days, modeling in 1 hour after the last administration.Except that normal group, other each treated animal equal subcutaneous injection adrenalin hydrochloride injection (0.06mg/kg) is put into frozen water (4 ℃) with animal behind the 2h and is soaked 5min, and taking-up is dried, and injects the Isodose adrenalin hydrochloride behind the 2h once more, then fasting 20h.Abdominal aortic blood detects its whole blood viscosity with the hemorheology instrument, packed cell volume, and erythrocyte aggregation index, the erythrocyte rigidity index, erythrodegeneration index, whole blood are just cut indexs such as reduced viscosity.The data mean ± standard deviation
The statistical result of SPSS 11.5for windows statistical software is used in expression, and measurement data is checked with variance analysis, Student-Newman-Keul; P＜0.05 is a significant difference for difference has statistical significance, P＜0.01.
1.1.BC capsule is to the influence (table 1) of Blood stasis rat whole blood viscosity.
Table 1.BC capsule is to the influence of Blood stasis rat whole blood viscosity
Annotate: relatively compare with model group #p＜0.05 with normal group * p＜0.01
1.2.BC capsule is to the influence (table 2) of Blood stasis rat packed cell volume, rigidity index, aggregate index and deformation index.
Table 2.BC capsule is to the influence of Blood stasis rat packed cell volume, rigidity index, aggregate index and deformation index
Annotate: relatively compare with model group #p＜0.05 with normal group * p＜0.01
Experimental result shows:
(1) the middle and high dosage group of BC capsule can obviously reduce whole blood viscosity under the low shear rate, compares with model control group, and difference has statistical significance (P＜0.05).BC Capsules group height, middle dosage group are better than the aspirin group aspect the viscosity reducing low the cutting of whole blood, and difference has statistical significance (P＜0.05).And reducing aspect the whole blood viscosity 30/s not as good as TONGXINLUO JIAONANG group (P＜0.05).
(2) the middle and high dosage group of BC capsule all has tangible reduction effect to Blood stasis rat packed cell volume and erythrocyte aggregation index, compares with model group, aspirin group and Tongxinluo group, and difference has statistical significance (P＜0.05).
(3) show that in conjunction with two experimental results this Chinese medicine composition has the hemorheological effect of obvious improvement.
(4) all do not find toxic and side effects in each dosage group of BC capsule.
Effect experiment 2:BC capsule is induced the protective effect of rat heart muscle ischemia to isoproterenol
70 of SD rats, male, body weight (160 ± 20) g, be divided into 7 groups at random, every group 10, be respectively normal control group, model control group, Western medicine positive controls (metoprolol 10mg/kg), Chinese medicine positive controls (TONGXINLUO JIAONANG 500mg/kg), BC Capsules group senior middle school low dose group (968,484,242mg/kg), medicine be dissolved in the deionized water of 2ml gastric infusion.Normal control group and model control group are given with the volume deionized water, and each organizes equal administration every day 1 time, continuously 14d.Except that the normal control group, all the other respectively irritate the stomach group all in the 12nd, 13,14 day gastric infusion 30min pneumoretroperitoneum injection isoproterenol (ISO) 5mg/kg, preparation rat heart muscle ischemic injuries model.Before injecting ISO for the first time, reach last injection ISO after 30 minutes, give 20% urethane anesthetized rat, it is subcutaneous that electrocardiographicelectrodes electrodes is inserted extremity respectively, record standard limbs mark II lead electrocardiogram, carry out self relatively with electrocardiogram before the modeling, observe whether the myocardial ischemia change takes place.Gather serum after weighing, measure serum superoxide dismutase (SOD), malonaldehyde (MAD), lactic acid dehydrogenase (LDH), the activity of alkali phosphatase (CK).Open breast and take out heart, weigh, conventional H E dyeing, the situation of change of under optical microscope, observing myocardium pathological tissue.The data mean ± standard deviation
The statistical result of SPSS 11.5for windows statistical software is used in expression, and measurement data is checked with variance analysis, Student-Newman-Keul; P＜0.05 is for difference has statistical significance, and P＜0.01 is a significant difference.
2.1.BC capsule is to the influence (table 3) of heart weight with the ratio of body weight of rat.
Table 3.BC capsule is to the influence of heart weight with the ratio of body weight of rat
Annotate: * p＜0.01, compare #p＜0.05 with normal group, compare with model group
2.2. influence to the every index of serology.
2.2.1.BC capsule is to rat SOD, the active influence of MDA (table 4).
Show the 4.BC capsule to rat SOD, the active influence of MDA
Annotate: * p＜0.01, compare #p＜0.05 with normal group, compare ※ p＜0.01 with model group, compare with model group
2.2.2.BC capsule is to rat LDH, the active influence of CK (table 5).
Show the 5.BC capsule to rat LDH, the influence of CK
Annotate: * p＜0.01, compare #p＜0.05 with normal group, compare ※ p＜0.01 with model group, compare with model group
2.3. influence (table 6) to ECG T wave.
Table 6.BC capsule is to the influence of rat ECG T wave
Annotate: * p＜0.01, compare #p＜0.05 with normal group, compare ※ p＜0.01 with model group, compare with model group
2.4. influence to cardiac muscular tissue
(table 7).
Standards of grading are divided into 6 grades with myocardium pathology, difference correspondence 0,1,2,3,4,5 minutes.0) intact disorders of blood kitchen range; 1) 1-5 ischemia focus; 2) an ischemia focus＞5; 3) endocardial areas ischemia focus is less than 1/2nd; 4) endocardial areas ischemia focus is greater than 1/2nd; 5) saturating wall ischemia kitchen range is less than 1/2nd circumferential areas; 6) saturating wall ischemia kitchen range is greater than 1/2nd circumferential areas.
Table 7.BC capsule pathological score table
Annotate: * p＜0.01, compare #p＜0.05 with normal group, compare with model group
Experimental result shows:
(1) in the ratio of and body weight heavy at each group heart, BC capsule in high dose group and model group relatively, the ratio reduction, difference has statistical significance (P＜0.05).
(2) high dose group SOD activity increases in the BC capsule, and MDA is active to be reduced, and difference has statistical significance (P＜0.05).
(3) compare with model group, the dosage group can reduce the LDH activity in the BC capsule, and difference has statistical significance (P＜0.05), and high dose group all can reduce the CK activity in the BC capsule, and difference has statistical significance (P＜0.05).
(4) except that BC capsule low dose group, each group changes difference with model group comparison T ripple all statistical significance (P＜0.05).
(5) histopathology is observed: at the normal myocardium tissue, organizational structure is clear, and cellular morphology is normal.In model group, pathological changes changes significantly, the organizational structure disorder, and large stretch of myocyte's disintegrate disappears, the lamellar necrosis, a large amount of monocyte infiltrations, primary cellular defect is serious.BC capsule in high dose group, the organizational structure lesion degree is better than model group, and there are the dead and monocyte infiltration of a small amount of kitchen range senile appearance in part myocyte's degeneration, abundant, the engrain of endochylema.Pathology standard appraisal result shows that model group and normal group comparing difference be (P＜0.01) significantly, compares with model group, and the downright bad score value of BC capsule in high dose group pathology reduces, and difference has statistical significance (P＜0.05).
(6) reduce Serum LDH, CK in conjunction with above-mentioned BC capsule height, middle dosage group, MDA activity (P＜0.05), and the activity (P＜0.05) of increase SOD, and the T wave-amplitude is reduced, cardiac muscular tissue's pathological changes is obviously improved.In the activity that reduces sero-enzyme with reduce that the aspect is better than metoprolol aspect the T ripple, relatively act on similarly to TONGXINLUO JIAONANG, but be not so good as metoprolol aspect cardiac muscular tissue's pathology improving.By to SOD, the active influence of MDA, the generation that prompting BC capsule may be by intervening oxygen-derived free radicals or strengthen oxygen radical removing is kept myocardial cell oxidation and antioxidation balance, thereby has been brought into play the damaging action that resists myocardial ischemia.By reducing LDH, myocardium enzyme such as CK prove that the BC capsule can alleviate the cardiac damage due to different third kidney, thereby protecting myocardial cell are improved myocardial ischemia.
(7) all do not find toxic and side effects in each dosage group of BC capsule.
To sum up, the technology of Chinese medicine composition of the present invention, prescription all belong to the innovative new drug that country advocates, because its novelty, safety and effectiveness have determined it to have market value preferably.The used medicine material of this Chinese medicine is medicine commonly used in addition, and the medicine source is extensive, and is cheap and easy to get, the production technology standard, and quality standard is controlled easily, so this service of goods of Development and Production is actively feasible in society.
Claims (3)
1. one kind has the Chinese medicine composition that improves myocardial ischemia and the effect of blood viscous state, it is characterized in that it is the medicament that is prepared from by following raw materials by weight proportions: Radix Notoginseng total arasaponins 4-8 part, Herb Gynostemmae Pentaphylli total glycosides 4-8 part, Folium Bambosae extract 3-5 part, Hirudo fine powder 15-30 part.
2. according to claim 1 have a Chinese medicine composition that improves myocardial ischemia and the effect of blood viscous state, it is characterized in that the weight proportion of crude drug is: 5 parts of Radix Notoginseng total arasaponinss, 5 parts of Herb Gynostemmae Pentaphylli total glycosidess, 4 parts of Folium Bambosae extract, 20 parts of Hirudo fine powders.
3. preparation claim 1 or 2 described preparation methoies with the Chinese medicine composition that improves myocardial ischemia and the effect of blood viscous state is characterized in that, may further comprise the steps successively:
Take by weighing Radix Notoginseng total arasaponins, Herb Gynostemmae Pentaphylli total glycosides, Folium Bambosae extract and Hirudo pulvis subtilis respectively according to weight proportion, and with above-mentioned four kinds of crude drug uniform mixing;
Evenly spray said mixture with 95% ethanol, wet granulation is crossed the 20-30 eye mesh screen, wet granular is put into drip pan carry out freeze-day with constant temperature, and baking temperature is no more than 50 ℃, dry 6-7 hour to moisture be 8%;
The granule that drying is good is put into granulation machine and is carried out granulate, makes the above capsule, tablet or granule of pharmaceutics according to conventional method.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010142461 CN102210815A (en) | 2010-04-08 | 2010-04-08 | Chinese medicine composition with functions of improving myocardial ischemia and blood viscosity and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201010142461 CN102210815A (en) | 2010-04-08 | 2010-04-08 | Chinese medicine composition with functions of improving myocardial ischemia and blood viscosity and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102210815A true CN102210815A (en) | 2011-10-12 |
Family
ID=44742499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201010142461 Pending CN102210815A (en) | 2010-04-08 | 2010-04-08 | Chinese medicine composition with functions of improving myocardial ischemia and blood viscosity and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102210815A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1907309A (en) * | 2005-08-02 | 2007-02-07 | 孙毅 | Cardiac and cerebral vascular disease treating and preventing medicinal composition |
-
2010
- 2010-04-08 CN CN 201010142461 patent/CN102210815A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1907309A (en) * | 2005-08-02 | 2007-02-07 | 孙毅 | Cardiac and cerebral vascular disease treating and preventing medicinal composition |
Non-Patent Citations (3)
| Title |
|---|
| 《江西中医学院学报》 20070228 张涵等 中药有效部位抗心肌缺血作用机制研究进展 第85-88页 1-3 第19卷, 第1期 * |
| 《生物质化学工程》 20080531 何跃君等 竹叶提取物的有效成分及其应用研究进展 第31-38页 1-3 第42卷, 第3期 * |
| 《铁道医学》现名《现代医学》 19910831 濮家伉等 绞股蓝总皂甙对大鼠缺血心肌心功能的影响 第193-195页 1-3 第19卷, 第4期 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103041118B (en) | Composition with effects of reducing blood sugar and reducing blood lipid | |
| CN102302555A (en) | Chinese medicinal extract for treating urarthritis, as well as preparation method and application thereof | |
| CN103127232A (en) | Total extract for mulberry leaf prescription as well as preparation and usage thereof | |
| CN102114102B (en) | Traditional Chinese medicine extract mixed preparation and application thereof | |
| CN103083400A (en) | Drug for treating cardiovascular disease | |
| CN104173451B (en) | The application in blood sugar lowering medicine and health food of a kind of natural drug composition | |
| CN104224885A (en) | Traditional Chinese medicine composition for relieving physical fatigue | |
| CN102475830B (en) | Medicinal composition for treating coronary disease and angina pectoris, preparation method thereof and preparation thereof | |
| CN103479963A (en) | Traditional Chinese medicine capsules for treating rheumatoid arthritis and preparation method thereof | |
| CN102784248B (en) | Chinese medicine composition for preventing and treating alcoholic liver injury | |
| CN101172155A (en) | Novel dosage forms of pulse-activating gallbladder warming soup and method of preparing the same | |
| CN101011562A (en) | Novel formulation of shenqiwendan decoction and production method thereof | |
| CN103830436A (en) | Traditional Chinese medicine composition for treating hypertension and preparation method thereof | |
| CN103385931B (en) | Blood-sugar-lowering medicine composition | |
| CN102631482B (en) | Chinese medicinal composition for preventing and treating diabetes and complications | |
| CN102210815A (en) | Chinese medicine composition with functions of improving myocardial ischemia and blood viscosity and preparation method thereof | |
| CN105343660A (en) | Traditional Chinese medicinal preparation for treating peripheral vertigo and preparation method of traditional Chinese medicinal preparation | |
| CN1150839C (en) | Health food with blood pressure and blood lipoid regulating function and its production process | |
| CN105663224A (en) | Composition for treating cardiovascular and cerebrovascular diseases and preparation thereof | |
| CN103055122A (en) | Medicine for preventing restenosis after intracoronary stent implantation and preparation method thereof | |
| CN103623109A (en) | Traditional Chinese medicine composition for treating ischemic cerebrovascular disease and preparation method thereof | |
| CN111759891B (en) | Pharmaceutical composition for treating myocardial ischemia and application thereof | |
| CN113521131B (en) | Traditional Chinese medicine composition for ischemic cardiomyopathy and application thereof | |
| CN102125590B (en) | Ginsenoside Rg1-containing pseudo-ginseng active ingredient as well as preparation method and application thereof | |
| CN101284052B (en) | Chinese medicinal materials compound prescription for treating the tumor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20111012 |